BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27569930)

  • 1. Impact of Histological Factors of Hepatocellular Carcinoma on the Outcome of Liver Transplantation.
    Donat M; Alonso S; Pereira F; Ferrero E; Carrión L; Acin-Gándara D; Moreno E
    Transplant Proc; 2016; 48(6):1968-77. PubMed ID: 27569930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
    Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
    Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential predictive factors for microvascular invasion in hepatocellular carcinoma classified within the Milan criteria.
    Imura S; Teraoku H; Yoshikawa M; Ishikawa D; Yamada S; Saito Y; Iwahashi S; Ikemoto T; Morine Y; Shimada M
    Int J Clin Oncol; 2018 Feb; 23(1):98-103. PubMed ID: 28875240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation.
    Choi HJ; Kim DG; Na GH; Hong TH; Bae SH; You YK; Choi JY; Yoon SK
    Liver Transpl; 2017 Aug; 23(8):1023-1031. PubMed ID: 28480517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.
    Varona MA; Soriano A; Aguirre-Jaime A; Garrido S; Oton E; Diaz D; Portero J; Bravo P; Barrera MA; Perera A
    Transplant Proc; 2015; 47(1):84-9. PubMed ID: 25645778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological differentiation predicts post-liver transplantation survival time.
    Li WX; Li Z; Gao PJ; Gao J; Zhu JY
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
    Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
    Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
    JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Within the Milan Criteria.
    Lei Z; Li J; Wu D; Xia Y; Wang Q; Si A; Wang K; Wan X; Lau WY; Wu M; Shen F
    JAMA Surg; 2016 Apr; 151(4):356-63. PubMed ID: 26579636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
    Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
    Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microvascular infiltration has limited clinical value for treatment and prognosis in hepatocellular carcinoma.
    Portolani N; Baiocchi GL; Molfino S; Benetti A; Gheza F; Giulini SM
    World J Surg; 2014 Jul; 38(7):1769-76. PubMed ID: 24378549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
    Zhang Q; Shang L; Zang Y; Chen X; Zhang L; Wang Y; Wang L; Liu Y; Mao S; Shen Z
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):544-52. PubMed ID: 24614696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
    Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
    Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma: Predicting Prognosis After Living-donor Liver Transplantation.
    Iguchi T; Shirabe K; Aishima S; Wang H; Fujita N; Ninomiya M; Yamashita Y; Ikegami T; Uchiyama H; Yoshizumi T; Oda Y; Maehara Y
    Transplantation; 2015 Jun; 99(6):1236-42. PubMed ID: 25427164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
    Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
    United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for extrahepatic recurrence of hepatocellular carcinoma following liver transplantation.
    Andreou A; Bahra M; Schmelzle M; Öllinger R; Sucher R; Sauer IM; Guel-Klein S; Struecker B; Eurich D; Klein F; Pascher A; Pratschke J; Seehofer D
    Clin Transplant; 2016 Jul; 30(7):819-27. PubMed ID: 27107252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.